Fibrosis Stabilization via Multi-Target Pathway Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrosis, such as anti-inflammatory drugs and non-selective anti-proliferatives, are ineffective in stopping fibrotic processes while allowing physiological healing, leading to severe organ damage and limited treatment options for conditions like pulmonary, renal, and hepatic fibrosis.
Innovation Solution
A method involving biological dataset profiling using BioMAP Systems to identify candidate agents that inhibit matrix remodeling, promote wound healing, protect epithelial health, control provisional fibrin matrix deposition, and exhibit anti-inflammatory activities, thereby stabilizing or reversing fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If anti-inflammatory drugs are used to treat fibrosis, then inflammation is reduced, but fibrotic processes are not stopped and tissue repair is impaired
Solution Approach 1:
The invention segments the complex fibrotic process into distinct pathways and targets specific components (TGF-β signaling, PDGF receptors, CTGF, FGF, IGF, VEGF, Angiotensin II, endothelin, thromboxane, prostaglandins, leukotrienes) rather than using broad-spectrum anti-inflammatory drugs. This selective targeting allows inhibition of fibrotic processes while preserving necessary inflammatory responses for tissue repair.
Solution Approach 2:
The invention changes the therapeutic parameter from general anti-inflammatory action to specific modulation of fibrotic pathway activity. By targeting molecular parameters such as TGF-β receptor signaling, PDGF receptor phosphorylation, and other specific biochemical parameters, the treatment achieves fibrosis stabilization without the side effects of broad anti-inflammatory therapy.
2Reliability
If non-selective anti-proliferatives are used to inhibit fibroblast proliferation, then fibrotic tissue formation is reduced, but physiological wound healing is impaired
Solution Approach 1:
The invention applies local quality by directing anti-proliferative effects specifically to activated myofibroblasts and fibroblasts involved in fibrotic processes, while sparing epithelial cells and other cell types necessary for physiological wound healing. Targeted inhibition of PDGF receptors, TGF-β signaling, and other fibrotic pathways achieves selective action on fibrotic tissue without impairing normal tissue repair mechanisms.
3Reliability
If current fibrosis treatments are applied, then some fibrotic activity is reduced, but organ architecture is not restored and treatment options are limited
Solution Approach 1:
The invention provides a universal multi-target approach that addresses multiple fibrotic pathways simultaneously (TGF-β, PDGF, CTGF, FGF, IGF, VEGF, Angiotensin II, endothelin, thromboxane, prostaglandins, leukotrienes). This multi-functional inhibition of diverse fibrotic mechanisms offers broader treatment effectiveness across different organ systems and fibrosis etiologies, restoring organ architecture where previous single-target therapies failed.
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
Agents that stabilize and/or prevent fibrosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on matrix deposition and remodeling, epithelial health, and inflammation. Treatment for fibrosis is provided using compositions of the invention.